Resources Management Corp CT ADV Raises Holdings in Abbott Laboratories $ABT

Key Points

• Resources Management Corp CT ADV sharply increased its Abbott Laboratories stake by 276.3% in the fourth quarter, bringing its holdings to 53,158 shares valued at about $6.66 million.
• Abbott insiders also bought shares recently, with CFO Philip P. Boudreau purchasing 2,200 shares and Director Daniel J. Starks buying 10,000 shares, signaling confidence from management.
• Abbott reported better-than-expected quarterly results and reiterated FY2026 guidance, while maintaining its dividend streak with a 410th consecutive quarterly dividend of 63 cents per share.

Resources Management Corp CT ADV boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 276.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,158 shares of the healthcare product maker's stock after acquiring an additional 39,031 shares during the quarter. Resources Management Corp CT ADV's holdings in Abbott Laboratories were worth $6,660,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. American National Bank of Texas boosted its holdings in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker's stock valued at $427,000 after acquiring an additional 79 shares during the period. Nia Impact Advisors LLC boosted its holdings in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock valued at $504,000 after acquiring an additional 79 shares during the period. Park Place Capital Corp boosted its holdings in Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker's stock valued at $102,000 after acquiring an additional 81 shares during the period. Lantern Wealth Advisors LLC boosted its holdings in Abbott Laboratories by 1.7% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker's stock valued at $674,000 after acquiring an additional 84 shares during the period. Finally, Clayton Financial Group LLC boosted its holdings in Abbott Laboratories by 1.4% during the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker's stock valued at $779,000 after acquiring an additional 84 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau bought 2,200 shares of the firm's stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company's stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ABT has been the subject of several analyst reports. Mizuho dropped their target price on Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a report on Friday, April 17th. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a report on Wednesday, May 27th. Stifel Nicolaus lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a research report on Friday, April 17th. Jefferies Financial Group lowered their price target on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating for the company in a research report on Friday, April 17th. Finally, Piper Sandler lowered their price target on Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $118.38.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Trading Down 0.3%

ABT opened at $87.89 on Monday. The business has a 50 day simple moving average of $91.46 and a two-hundred day simple moving average of $107.84. The firm has a market capitalization of $153.08 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 1.47 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. Abbott Laboratories's dividend payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.